Centene price target raised to $45 from $42 at Truist

Truist raised the firm’s price target on Centene (CNC) to $45 from $42 and keeps a Buy rating on the shares. The company’s Q3 results saw top and bottom-line beats, consolidated health benefits ratio, HBR, that was a bit better, coupled with sequential improvement in Medicaid HBR and upped FY25 guidance, the analyst tells investors in a research note. High-level 2026 commentary was encouraging, with expectations of Medicaid profitability consistent with FY25, the firm added.